Verification evidence is still being completed.
PDF / print export
Antion Biosciences SA
Geneva, Switzerland
- Verified lead
- Marco Alessandrini
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Multiplex miRNA Gene Silencing, Allogeneic CAR-T Cell Therapy, and Cell and Gene Engineering
- Review cycle
- 24 April 2026
- Full address
- Geneva, Switzerland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- GlobeNewswire 2024 release naming Marco Alessandrini as CEO of Antion Biosciences.
- Editorial note
- Geneva cell and gene therapy biotech with named CEO, University of Geneva lineage, miCAR7 allogeneic CAR-T lead, and proprietary multiplex miRNA gene-silencing platform.
Multiplex miRNA Gene Silencing, Allogeneic CAR-T Cell Therapy, and Cell and Gene Engineering
University of Geneva spin-off, Public CEO disclosure via GlobeNewswire, Swiss Biotech Association listing
Geneva cell and gene therapy biotech with named CEO, University of Geneva lineage, miCAR7 allogeneic CAR-T lead, and proprietary multiplex miRNA gene-silencing platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated07 Jul 2026, 01:10
Company profile · Geneva, Switzerland
Antion Biosciences SA
Multiplex miRNA Gene Silencing, Allogeneic CAR-T Cell Therapy, and Cell and Gene Engineering · Preclinical cell-therapy development
Verified 24 Apr 2026 · 3 sources
Cell TherapyGene TherapyDiscovery
Geneva cell and gene therapy biotech with named CEO, University of Geneva lineage, miCAR7 allogeneic CAR-T lead, and proprietary multiplex miRNA gene-silencing platform.
Contact & location
- Address
- Geneva, Switzerland
- Website
- antionbio.com
- Company page
- Lead
- Marco Alessandrini (verified ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (2mo ago)
- Scale
- Preclinical cell-therapy development
- Capabilities
- Multiplex miRNA Gene Silencing Platform · Allogeneic CAR-T Development · Cell and Gene Engineering
- Founded
- 2018
- Headcount
- 11-50
Multiplex miRNA Gene Silencing, Allogeneic CAR-T Cell Therapy, and Cell and Gene Engineering
Geneva cell and gene therapy biotech with named CEO, University of Geneva lineage, miCAR7 allogeneic CAR-T lead, and proprietary multiplex miRNA gene-silencing platform.
Editorial note
Antion Biosciences is a University of Geneva spin-off (founded 2016) with a named CEO and a proprietary multiplex miRNA gene-silencing platform supporting the miCAR7 allogeneic CAR-T lead.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Verification details
Clinical profileSTATUS: VERIFIED APRIL 2026
Marco Alessandrini
Chief Executive Officer
Full addressGeneva, Switzerland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Preclinical cell-therapy development
Geneva, Switzerland. Multiplex miRNA Gene Silencing, Allogeneic CAR-T Cell Therapy, and Cell and Gene Engineering. Review completed on 24 Apr 2026.
Swissmedic, EMA, and FDA for future clinical development
University of Geneva spin-off, Public CEO disclosure via GlobeNewswire, Swiss Biotech Association listing
Capabilities
Multiplex miRNA Gene Silencing Platform
Allogeneic CAR-T Development
Cell and Gene Engineering
Sources
The official sources used to verify this profile.
Infrastructure
miRNA gene-silencing platform
CAR-T cell engineering workflow
Preclinical in vivo models
Certifications
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Review log
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
Frequently asked questions
- Where is Antion Biosciences SA located?
- Antion Biosciences SA operates from Geneva, Switzerland, Geneva, Switzerland.
- Who runs Antion Biosciences SA?
- Antion Biosciences SA is led by Marco Alessandrini, Chief Executive Officer. Verified 24 Apr 2026.
- What does Antion Biosciences SA do?
- Geneva cell and gene therapy biotech with named CEO, University of Geneva lineage, miCAR7 allogeneic CAR-T lead, and proprietary multiplex miRNA gene-silencing platform. Core capabilities: Multiplex miRNA Gene Silencing Platform, Allogeneic CAR-T Development, Cell and Gene Engineering.
Editorial context
Related technical briefs
Briefs that name Geneva as a covered market or city.